AS

Alek Safarian

CEO at ALSA Ventures

London, England

Investor
VC
CEO

Invests in

Stages:

Seed
Pre-seed

Locations:

United Kingdom

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Clinical Trials
CRO
Pharmaceutical Industry
Regulatory Affairs
Clinical Development
Medical Devices
Strategy
Biotechnology
CTMS
Informatics
Medical Writing
Clinical Research
Mergers & Acquisitions
Infectious Diseases
Pharmacovigilance
Diabetes
Vaccines
GCP
Oncology
Sop

Education

Lists including Alek

AP
AO
AS
AN

Based in UK

1884 people

AM
AT
AS
AR

All Seed Investors

19695 people

AT
AE
AE
AL

All Pre-Seed Investors

7974 people

Work Experience

AV
ALSA Ventures

2018

  • CEO

    2018

N
Novotech

1996 - 2017

  • Member of the Board of Directors

    1996 - 2017

  • CEO

    1996 - 2017

    Executive responsibility for day to day operations of the company, setting strategy together with management team and board, executing on the company's growth strategy.

MM
Marion Merrell Dow (now Sanofi-Aventis)

1990 - 1995

  • Head, Scientific Affairs, Asia-Pacific

    1990 - 1995

    Based in Sydney, headed the regulatory affairs function and post-marketing research in 11 countries in the Asia-Pacific including Australia, China, Korea, Taiwan, and Singapore. Left MMD just before merger with Hoechst Roussel to found Novotech.

C(
Ciba-Geigy (now Novartis)

1988 - 1990

  • Regulatory Affairs Associate

    1988 - 1990